Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VXA-BYW-10
- Development stage
- Phase 1
- Lead developer
- Vaxart
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Adenoviral Vectors → Other Viral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Oral
01
Overview
VXA-BYW-10 is an orally administered, adenoviral vector-based vaccine developed for the prophylaxis of influenza B virus infection. It is designed to stimulate the immune system by acting as a TLR3 (Toll-like receptor 3) agonist, thereby enhancing immune responses against influenza B. The vaccine was developed by Vaxart and has been evaluated in phase 1 clinical trials to assess its safety and immunogenicity in healthy adults[1][2][4][7].
- Other names
- Influenza B Oral Vaccine
02
Targets
TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on VXA-BYW-10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VXA-BYW-10.